CLINICAL PHARMACOKINETICS OF CASPOFUNGIN IN CRITICALLY ILL PATIENTS DURING CONTINUOUS VENO-VENOUS HEMOFILTRATION - Caspofungin in hemofiltration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004106-87-AT

Enrollment

Registered

2007-10-15

Start date

2007-10-23

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) and continuous veno-venous hemofiltration

Interventions

Trade Name: Cancidas Product Name: Cancidas Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 179463173 Other descriptive name: CASPOFUNGIN ACETATE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Indication for treatment with caspofungin Indication for arterial line Age above 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: lacking indication/contraindication for caspofungin lacking indication/contraindication for arterial line lacking consent pregnancy age below 18 years

Design outcomes

Primary

Measure	Time frame
Main Objective: to assess plasma pharmacokinetics in critically ill patients undergoing continuous veno-venous hemofiltration (CVVH), and to compare it with that of critically ill patients not requiring renal replacement therapy;Secondary Objective: dosage guide lines for critically ill patients on CVVH will be established;Primary end point(s): Concentrations of caspofungin in plasma with/without hemofiltration	—

Measure

Time frame

Main Objective: to assess plasma pharmacokinetics in critically ill patients undergoing continuous veno-venous hemofiltration (CVVH), and to compare it with that of critically ill patients not requiring renal replacement therapy;Secondary Objective: dosage guide lines for critically ill patients on CVVH will be established;Primary end point(s): Concentrations of caspofungin in plasma with/without hemofiltration

—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026